Abstract: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a hereditary cancer syndrome in which affected individuals are predisposed to the development of multiple leiomyomas of the skin and uterus and aggressive forms of kidney cancer. Affected individuals harbor a germline heterozygous loss-of-function mutation of the fumarate hydratase (FH) gene. Uterine leiomyomas are present in up to 77% of women with this syndrome. Previous studies have shown that inactivation of the FH gene is unusual for nonsyndromic leiomyomas. Therefore, it might be possible to distinguish 2 genetic groups of smooth muscle tumors: the most common group of sporadic uterine leiomyomas without FH gene inactivation and the more unusual group of HLRCC leiomyomas in patients who harbor a germline mutation of FH, although the exact prevalence of hereditary HLRCC is unknown. We reviewed the clinical, morphologic, and genotypic features of uterine leiomyomas in 19 HLRCC patients with FH germline mutations. Patients with HLRCC syndrome were younger in age compared with those with regular leiomyomata. DNA was extracted by microdissection, and analysis of loss of heterozygosity (LOH) at 1q43 was performed. Uterine leiomyomas in HLRCC have young age of onset and are multiple, with size ranging from 1 to 8 cm. Histopathologically, HLRCC leiomyomas frequently had increased cellularity, multinucleated cells, and atypia. All cases showed tumor nuclei with large orangeophilic nucleoli surrounded by a perinucleolar halo similar to the changes found in HLRCC. Occasional mitoses were found in 3 cases; however, the tumors did not fulfill the criteria for malignancy. Our study also showed that LOH at 1q43 was frequent in HLRCC leiomyomas (8/10 cases), similarly to what has been previously found in renal cell carcinomas from HLRCC patients. LOH is considered to be the second hit that inactivates the FH gene. We conclude that uterine leiomyomas associated with HLRCC syndrome have characteristic morphologic features. Both, uterine leiomyomas and renal cell carcinoma share some morphologic nuclear changes and genotypic features in HLRCC patients. The specific morphologic features of the uterine leiomyomas that we describe may help in the identification of patients who may be part of the hereditary syndrome.
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Key Words: familial renal cancer syndrome, fumarate hydratase mutation, HLRCC, uterine leiomyoma (Am J Surg Pathol 2013;37:74-80) H ereditary leiomyomatosis and renal cell cancer (HLRCC) is a hereditary cancer syndrome in which affected individuals are predisposed to the development of leiomyomas of the skin and uterus. 1 In addition, affected individuals are also at risk for the development of an aggressive form of kidney cancer. 1 Of 13 individuals identified with kidney cancer in the first reported cohort of North American families, 9 patients succumbed to metastatic disease within 5 years from initial diagnosis. 2 Affected individuals harbor a germline heterozygous lossof-function mutation of the fumarate hydratase (FH) gene. 1, 3, 4 HLRCC is also known as multiple cutaneous and uterine leiomyomatosis syndrome. The exact prevalence of HLRCC is unknown. Kidney cancers are less penetrant than leiomyomatous manifestations in HLRCC-affected families. 4 Cutaneous leiomyomas were first identified in 1854. 5 The association between cutaneous and uterine leiomyomas has been known for many years as Reed syndrome. 6 Leiomyomatosis is a condition defined by the occurrence of multiple leiomyomas throughout the body, with often poorly defined nodules that invade areas of the skin on the arms, chest, legs, and in extremely rare cases, the uterus. Renal tumors have been identified in approximately one third of HLRCC families. To consider the possibility of HLRCC or screening for renal cell cancer in leiomyomatosis is an important issue that needs to be addressed. There is conflicting evidence about the frequency of germline FH mutations in patients with cutaneous leiomyomas (ranging from none to 80%). Uterine leiomyomas are present in up to 77% of women. In this report we describe specific morphologic changes in the uterine leiomyomas of HLRCC patients that may provide additional helpful information to identify patients who may be part of the familial HLRCC syndrome.
MATERIALS AND METHODS
Nineteen female members of families with known HLRCC syndrome and with multiple uterine leiomyomas were studied. All patients had been evaluated at the Urologic Oncology Branch of the National Cancer Institute under an approved protocol by the Institutional Review Board of the National Cancer Institute. Appropriate informed consents were obtained. Patients were interviewed for history of cutaneous leiomyomas, uterine leiomyomas, hysterectomy, and renal tumors. Uterine leiomyomas were documented by history, review of medical records, physical examination, magnetic resonance imaging, computed tomography, and/or ultrasonography. All hematoxylin and eosin slides (with a minimum of 3) from all cutaneous, renal, and uterine lesions were obtained for review.
Morphologic Definitions
We followed the World Health Organization standard histopathologic criteria for the diagnosis of smooth muscle tumors, 7 which are summarized as follows: histologically, the leiomyomas showed well circumscribed nodular arrangements of interlacing bundles of smooth muscle fibers with a large centrally located blunt-edged nucleus. There was no evidence of atypia or coagulative necrosis, and r5 mitoses per 10 high-power fields (HPF) were observed. Cellular leiomyomas showed increased cellularity without significant nuclear pleomorphism with no evidence of coagulative tumor cell necrosis and presence of <5 mitoses per 10 HPF. Atypical leiomyomas (AL) had increased cellularity and marked cellular pleomorphism with occasional mitotic figures ( < 10 mitoses per 10 HPF, the World Health Organization criteria for malignancy for spindle cell-appearing smooth muscle tumor). No evidence of coagulative tumor cell necrosis or abnormal mitosis was found.
Sequencing of the FH Gene
DNA was extracted from peripheral blood leukocytes according to standard procedures. The genomic sequence containing FH was determined by BLAST alignment of the mitochondrial FH precursor cDNA (Acc. No. NM_000143) with the assembled genomic sequence (NCBI build 34). Methods for identification of exon/intron boundaries and high-throughput DNA sequencing were as previously described.
Loss of Heterozygosity Analysis

DNA Extraction From Microdissected Samples
Manually microdissected normal and procured tumor cells were resuspended in a solution containing 0.1 mg/mL proteinase K and incubated for 48 hours at 551C. The mixture was boiled for 10 minutes to inactivate proteinase K, and 1.5 mL of this mixture was used as a template in each polymerase chain reaction (PCR)-based microsatellite analysis.
PCR Analysis
Matched tumor and normal cells from the same patient were subjected to PCR analysis. Fluorescent-labeled primers were obtained from Research Genetics (Huntsville, AL). Oligonucleotide primers flanking microsatellite polymorphisms at D1S517S1S2785AFM214D1S547D1S2482 were used in the study. The markers were located 2.2, 0.8, and 0.2 Mbp to the left, at AFM214 within the gene, and 0.1 and 2 Mbp to the right of the FH gene on chromosome 1. The fluorescently labeled PCR primers used to amplify From left to right: D1S517, D1S2875, D1S180, FH gene with the AFM214 microsatellite marker within the sequence, D1S547, and D1S2842. In each case, the box representing each marker can appear as filled in black when LOH was detected, white when the results were not informative, or empty when heterozygous. In cases in which LOH was found, the wide allelic loss was determined with all the informative microsatellite markers (black arrows covering the deleted chromosomal region). Identical LOH patterns were found in different leiomyomas studied from the same patient (cases 2 and 4). CL indicates cellular leiomyoma; SMTUMP, smooth muscle tumors of uncertain malignant potential.
Am J Surg Pathol Volume 37, Number 1, January 2013 Atypical Leiomyomata in HLRCC Syndrome analysis was complete. Only primers that demonstrated heterozygosity in normal cell DNA were considered informative. Noninformative cases included those with homozygous alleles in normal tissue and cases in which allelic patterns could not be clearly distinguished by the capillary electrophoretic methods used. Allelic loss (LOH) was calculated by comparison of the allele ratio of normal cells with the allele ratio in fibroid and tumor cells. The criterion for LOH was at least a 40% reduction of the lesional allele with the subsequent modification of the allele ratio (Fig. 4) . To assess the reproductability of the LOH patterns, we microdissected different areas from the same tumor section. A consistent pattern was observed in all cases when studies were repeated (data not shown). Table 1 summarizes the results of our study. Patients ranged in age from 24 to 47 years (median, 32 y). The leiomyomas were histopathologically diagnosed as cellular leiomyomas (6 cases) and ALs (13 cases). Nine patients had a previous history of cutaneous leiomyomas, and 5 had a previous history of renal cancer. Leiomyomas were multiple in all patients, with maximum size ranging from 1 to 8.5 cm. Histopathologically, HLRCC uterine leiomyomas were well circumscribed and were fascicular tumors that frequently had increased cellularity and nuclear atypia. The most characteristic change was the presence in every case of occasional cells that had large multinucleated or single nuclei showing orangeophilic prominent nucleoli surrounded by a perinucleolar halo (Fig. 1) . These inclusionlike nucleoli are seen in renal cancer cells (Fig. 2) but not in cutaneous leiomyomas from HLRCC patients. This finding can be seen on low power and is variably extensive throughout the tumor with focal distribution. Although occasionally mitoses were found (Table 1) , tumors did not fulfill established criteria of malignancy. No evidence of coagulative tumor cell necrosis or atypical mitosis was seen in any of these cases.
RESULTS
The LOH analysis is shown in Table 1 . Table 1 mutation, the exon and codon affected by the mutation and the nucleotide and amino acid change. Different FH exons were affected with a higher incidence of exon 7 (3 cases), and 8 (4 cases) mutations were noted. The LOH analysis demonstrated allelic loss in 8 of 10 cases in which DNA was available (80%). Figure 3 shows the LOH patterns detected with various markers flanking the FH gene. In cases in which LOH was found, it was consistent with a partial loss of chromosome 1q43. The wide allelic loss was determined with all the informative microsatellite markers (arrows covering the deleted chromosomal region). Identical LOH patterns were found in different leiomyomas studied from the same patient (cases 2 and 4). Both ALs and cellular leiomyomas were analyzed in case 2, and all showed the same LOH pattern (Fig. 4) .
DISCUSSION
The present study describes the morphologic changes found in the uterine smooth muscle tumors of female patients with HLRCC syndrome. Smooth muscle tumors associated with this syndrome occur predominantly in younger women who present with severe history of irregular bleeding that required hysterectomy. HLRCC leiomyomas frequently showed histopathologic features consistent with cellular or atypical uterine leiomyomas. All cases showed tumor nuclei that contained inclusion-like nucleoli that were orangeophilic, with a perinucleolar halo; these changes were similar to those found in HLRCC nuclei. 8 This histopathologic feature can be considered the hallmark of both uterine leiomyomas and HLRCC. In the original description of HLRCC, it was reported that 2 of 11 women with uterine leiomyomas also had uterine leiomyosarcoma. 1 To date, 6 women with a germline mutation in FH have been reported with uterine leiomyosarcoma. 9 In our series, no evidence of coagulative tumor cell necrosis or abnormal mitosis was found, and the tumors did not fulfill the criteria for malignancy. One patient underwent 2 separate surgeries with an interval time of 2 years during which a pregnancy occurred, but no morphologic changes were seen when the tumors were compared.Clinically, previous reports describe that uterine leiomyomas are present in almost all female individuals with HLRCC, they tend to be numerous and large, and are usually highly symptomatic. 2, 4, 10 The young age of onset of symptomatic uterine leiomyomas and the high risk of hysterectomy significantly impact the childbearing years of women with HLRCC. The average age for hysterectomy in HLRCC patients was 30 year versus 45 years in the general population. 2 The Krebs cycle enzyme, FH, acts as a tumor suppressor. Patients with HLRCC inherit a germline mutation of the FH gene as well as a wild-type copy. 3, 11, 12 Uterine tumor formation appears to occur when there is a somatic alteration of the wild-type copy. That "second hit" in most HLRCC tumors appears to take the form of allelic loss of the wild-type allele, consistent with absent or near-absent protein function as the cause of tumorigenesis. 13 The basic mechanism of tumorigenesis in HLRCC is likely to be a pseudohypoxic drive, similarly to the molecular pathway described in Von Hippel-Lindaudeficient kidney cancer. 3, [14] [15] [16] Our study also reveals that smooth muscle tumors associated with HLRCC have characteristic genotypic features. LOH at 1q43 is frequent (80%) in HLRCC leiomyomas suggesting a biallelic inactivation of the FH gene, 1 allele inactivated by the germline mutation and the other by LOH. The explanation for a "second hit" inactivating FH in the remaining cases in which no LOH was found could be either a second mutation in the coding sequence, nondetected small deletions, or hypermethylation of the promoter region. 17 Both FH mutations and LOH at 1q43 are genotypic features unusual in sporadic leiomyomas. Two studies showed no evidence of FH somatic mutations in 129 and 41 nonsyndromic leiomyomas. 11, 12 LOH analysis performed by Lehtonen and colleagues showed allelic loss at 1q43 in only 5 of 153 sporadic cases. 18, 19 Therefore, the loss of function of the FH gene, inactivating its potential role as a tumor suppressor gene in tumorigenesis and in activating the pseudohypoxic molecular pathway, appears to be more frequent in HLRCC leiomyomas than in sporadic leiomyomas. [20] [21] [22] Indeed, expression profiling studies by cDNA microarrays have shown that FH-mutant leiomyomas have a distinct expression profile of genes belonging to groups such as glycolysis, extracellular matrix, cell growth, cell adhesion, or muscle development when compared with sporadic wild-type FH gene leiomyomas. 13 We conclude that uterine leiomyomas associated with HLRCC syndrome have characteristic morphologic features. Both uterine leiomyomas and renal cancer cells share some morphologic nuclear changes and genotypic features in HLRCC patients. The specific morphologic features of the uterine leiomyomas we describe may be helpful additional features to identify patients that may undergo genetic testing for germline FH mutations and screening for renal cell cancer.
